Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 2/20 | 0.33 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 2/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.31 |
| ▸ | AVPR1B | P47901 | 2/20 | 0.30 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5238212 | 0.90 | RXFP1 (0.34) | PTGER4PTGER2CNR2CNR1S1PR3 | |
| SCHEMBL5235009 | 0.85 | DPP4 (0.38) | S1PR3 | |
| SCHEMBL5238484 | 0.85 | HPGD (0.37) | CNR2AVPR1B | |
| SCHEMBL5236293 | 0.84 | ALDH1A1 (0.41) | CNR2CNR1PLA2G2A | |
| SCHEMBL6703529 | 0.82 | DPP4 (0.35) | S1PR3 | |
| SCHEMBL5234470 | 0.81 | THRA (0.36) | CNR2CNR1PLA2G2AS1PR3 | |
| SCHEMBL5236977 | 0.80 | SMN1; SMN2 (0.34) | PTGER4PTGER2CNR2CNR1 | |
| SCHEMBL5234726 | 0.80 | THRB (0.34) | S1PR3 | |
| SCHEMBL5238558 | 0.79 | MAPK8 (0.41) | CNR2CNR1PLA2G2AS1PR3 | |
| SCHEMBL5234361 | 0.79 | HSD17B10 (0.36) | CNR2AVPR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040082607-A1 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082607-A1 | Fused heterocyclic compounds | DPP7, DPP4, METAP1 | PTGER4 2453/4885PTGER2 3097/4885CNR2 3755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.